查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837125

按器官類型、產品類型、捐贈者類型、手術類型和最終用戶分類的移植市場 - 2025-2032 年全球預測

Transplantation Market by Organ Type, Product Type, Donor Type, Procedure Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，移植市場規模將成長至 609.8 億美元，複合年成長率為 8.78%。

主要市場統計數據
基準年2024年 310.9億美元
預計2025年 338億美元
預測年份：2032年 609.8億美元
複合年成長率（%） 8.78%

簡要介紹臨床創新、保存技術和程序轉變如何重塑移植護理服務和商業性優先事項。

移植醫學正處於關鍵的十字路口，外科技術、生物技術和器官保存方法的進步正在重新定義臨床可能性。近期灌注和器官保存的創新，以及強化的免疫抑制方案，正在擴大移植的窗口，並使更複雜的手術成為可能。同時，捐贈者管理的轉變以及微創和機器人技術的興起正在改變醫療保健途徑，迫使醫院系統和醫療服務提供者重新思考其物流、採購和培訓框架。

本報告整合了臨床、技術、監管和付款方的動態，呈現了統一的高階主管觀點。報告重點介紹了產品系列（從導管、移植物和縫合線等耗材，到監測和灌注系統等設備，再到人工器官和血管移植物等植入）如何與不斷變化的手術選擇和供體特徵相互影響。本書將門診手術中心、醫院和專科診所的營運現狀與臨床結果和患者可近性的更廣泛趨勢聯繫起來。最後，本引言將移植定位為臨床複雜性與商業性機會交會的領域，為後續的詳細分析奠定了基礎。

手術方法、器官保存科學和以結果為中心的報銷模式的轉變如何改變移植生態系統

器官移植領域正在經歷一場變革性的轉變，這正在重新調整臨床、技術應用和政策環境的競爭優勢。臨床上，由於希望降低手術全期併發症發生率並加快復健速度，手術方式明顯從傳統的開放性手術轉向機器人輔助和腹腔鏡技術。這一趨勢的動力在於對免疫抑制精準管理的日益重視，以及旨在降低排斥反應並減輕長期副作用的新藥物和聯合策略。

技術變革同樣意義重大。器官灌注和保存方案的日趨成熟正在提高器官存活率，而監測設備的進步則使更細緻的手術全期和移植後管理成為可能。同時，從先進的血管移植物到新型人工器官原型，植入正從概念發展到臨床可行性，促使人們重新思考治療途徑。監管和報銷環境正在適應這些技術創新，支付方和醫療保健系統越來越重視患者治療效果和總護理成本的顯著改善。總而言之，這些力量並非漸進式的；它們正在重塑採購重點、臨床團隊能力以及醫療服務提供者和供應商之間的長期策略藍圖。

評估 2025 年美國關稅調整對器官移植供應鏈和採購彈性的營運和策略影響

2025年美國關稅政策的變化給整個移植供應鏈帶來了顯著壓力，影響了籌資策略、供應商關係和成本結構。某些進口零件和原料的關稅上調，增加了設備、耗材和植入製造商的到岸成本，迫使採購團隊重新考慮供應商多元化和近岸外包的選擇。這些變化也對庫存管理和前置作業時間緩衝產生了連鎖反應，因為醫療保健提供者需要在成本控制和保持對時間敏感的程序的連續性護理需求之間取得平衡。

作為應對措施，許多製造商加快了關鍵製造流程的本地化步伐，或尋找不易受關稅波動影響的替代來源。臨床和供應鏈領導者透過加強需求預測和協商強調韌性的服務水準協議來適應變化。此外，人們對基於價值的合約和捆綁支付結構重新產生了興趣，這些結構可以吸收意外的成本壓力，同時協調相關人員之間的獎勵機制。雖然法規合規性和品質保證仍然至關重要，但關稅上調引發了對供應韌性和策略採購的更廣泛重新評估，這將影響未來的供應商選擇和合作模式。

整合細分智慧，將臨床需求按器官、產品層次、捐贈途徑、程序偏好和護理環境聯繫起來，以提供策略優先排序資訊

策略優先排序是基於對特定器官臨床需求、產品層級、捐贈途徑、手術選擇和醫療環境的綜合考量。依器官類型分析顯示，心臟、腸道、腎臟、肝臟、肺臟和胰臟移植的臨床優先順序和設備需求有顯著差異。例如，器官特定的保存要求和術後監測方案決定了產品需求和臨床工作流程。從產品類型的角度來看，生態系涵蓋導管、移植物和縫合線等耗材；監測設備、灌注設備和保存液等設備；包括人工器官和血管移植物在內的植入；以及抗增殖藥物、鈣調磷酸酶抑制劑、Calcineurin固醇和mTOR抑制劑等藥物。此產品層級結構突顯了漸進式創新和供應限制對營運影響最大的領域。

將捐贈者類型細分為死者捐贈途徑和活體捐贈途徑，每種途徑都需要不同的物流和倫理考量，從而影響採購時間表、知情同意流程和術前最佳化。按手術類型細分，可以揭示與腹腔鏡手術、開放式手術和機器人手術相關的不同資源狀況和培訓需求，從而改變資本規劃和手術全期人員配置模式。最後，將門診手術中心、醫院和專科診所的最終用戶細分，可以說明醫療保健環境如何影響新技術的採用速度、採購週期以及與現有臨床網路的整合。整合這些視角，相關人員可以製定反映臨床細微差別和營運現實的策略，而不是一刀切的假設。

區域戰略觀點反映了美洲、歐洲、中東和非洲以及亞太地區的臨床能力、法律規範和採購規範的差異

區域動態影響整個移植領域的採用軌跡、監管格局和夥伴關係機會。在美洲，臨床卓越中心通常會推動先進器官保存系統和機器人技術的早期採用，而採購模式因公立和私立支付機構而異，從而影響採購週期和合約結構。歐洲、中東和非洲是一個多元化的地區，監管協調、基礎設施差異以及器官共用協議的跨境合作既創造了機遇，也帶來了營運複雜性。該地區通常強調多中心註冊和指南協調，以改善療效。

亞太地區的特點是外科手術能力的快速投入、臨床研究活動的活性化以及本地製造能力的提升，這些因素可能重塑全球供應關係。在每個地區，國家在報銷框架、勞動力發展管道和捐贈者登記方面的政策都會影響新技術從核准到常規應用的速度。因此，一個地區成功的商業策略往往需要重新調整，以應對另一個地區採購規範、監管預期和臨床實踐模式的差異，因此，制定符合區域情況的藍圖對國際參與者至關重要。

設備製造商、生物製藥公司和專業創新者之間的競爭與夥伴關係動態塑造了移植產品和服務的未來

移植醫學領域的競爭態勢並非由單一主導企業決定，而更取決於由設備製造商、製藥公司、醫院和利基市場創新者組成的生態系統的協同作用。現有的醫療設備製造商繼續利用其規模、監管經驗和分銷網路，將監測系統、灌注平台和植入式可用技術商業化。生物製藥公司正專注於下一代免疫抑制方案和輔助性治療，以延長移植器官的壽命並提高患者的生活品質。同時，規模較小的專業公司和學術衍生公司正在為器官保存化學、生物工程移植材料和人工器官開發等領域帶來顛覆性創新。

臨床中心與產業之間的合作加速了真實世界證據的生成，並支持了付款人的參與。併購通常源自於整合互補能力的願望，例如將設備平台與軟體支援的監控相結合，或為更廣泛的外科產品組合添加獨特的儲存解決方案。為了實現差異化，各公司正在投資於減少臨床摩擦的服務，例如培訓計劃、全面的維護以及用於手術全期協調的數位化工具。總體而言，那些將臨床提案主張與營運支援和持久的報銷策略相結合的組織正在取得成功。

為高階主管提供以行動為重點的策略性舉措，以增強供應彈性、加速臨床應用，並使價值交付與移植護理報銷保持一致

移植產業領導者應採取有針對性的策略，以增強韌性、加速臨床應用並協調相關人員的獎勵。首先，優先考慮供應鏈多元化，並認證關鍵零件的本地製造能力，以減輕關稅波動和對單一供應商的依賴。其次，投資臨床醫生培訓計畫和臨床證據生成，以證明患者治療效果改善、總事件成本降低，並促進與付款人的建設性對話。第三，設計配套服務，將設備、儲存解決方案、臨床培訓和術後監測相結合，以簡化採購並為醫院和專科診所提供可衡量的價值。

同時，高階主管應與高績效移植中心建立策略合作關係，共同開發和檢驗新技術，以加快其應用速度並形成令人信服的價值敘事。引入數位化工具，加強手術全期協調和遠端監控，以減少併發症並有效利用有限的專家資源。最後，積極與監管機構和報銷機構合作，制定政策框架，以認可先進器官保存技術和綜合護理模式的臨床和經濟效益。透過實施這些建議，組織可以將臨床創新轉化為永續的商業性優勢。

一種透明的調查方法，融合了文獻綜述、專家訪談和資料三角測量，為臨床和商業領域提供有效、可操作的見解

本研究結合定性和定量數據，結合系統性文獻研究、專家訪談和跨部門數據三角檢驗，建構了器官移植生態系統的整體情況。調查方法首先全面回顧同儕審查的臨床研究、監管申報和指南更新，以建立臨床和科學基礎。此外，還對移植外科醫生、採購主管、醫院管理人員和行業高管進行了結構化訪談，以了解操作細節、未滿足的需求和應用障礙。

分析了包括設備註冊、臨床試驗庫和公共文件在內的二手資訊，以檢驗趨勢並繪製技術就緒水平圖。應用三角測量技術來協調不同資訊來源之間的差異，並透過敏感度檢查確保操作性解讀在不同地區和醫療機構之間具有穩健性。最後，應用細分框架，根據器官類型、產品類型、供體途徑、程序類型和最終用戶情況整合洞察，從而能夠根據不同相關人員的優先事項制定切實可行的建議。在整個過程中，我們始終遵循倫理研究實務和資料完整性標準指南證據的選擇和整合。

綜合可操作的結論，強調決定移植臨床應用、營運彈性和商業性成功的趨同促進因素

總而言之，移植醫學正處於曲折點，技術進步、不斷變化的程序規範和不斷發展的政策框架正在匯聚，創造新的臨床和商業性軌跡。器官特異性臨床挑戰、包括耗材、器械、植入和藥品在內的多樣化產品組合以及多樣化的供體和手術環境的相互作用，凸顯了差異化策略的必要性。投資於彈性供應鏈、證據產生、臨床醫生參與和整合服務模式的組織將處於有利地位，能夠將創新轉化為持續的臨床影響。

展望未來，成功的關鍵在於駕馭區域監管多樣性，妥善處理採購和報銷動態，並建立夥伴關係以加速現實世界的推廣應用。透過專注於以患者為中心的成果、營運效率和協作價值交付，相關人員可以建立一個移植生態系統，改善移植的可近性、療效和長期移植物存活率，同時建立永續的商業性成長之路。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 擴大機器灌注技術的使用以提高供體器官的活力
  • 加大異種移植研究力度，解決器官短缺問題
  • 將人工智慧演算法整合到術前供體器官匹配工作流程中
  • 加強對細胞和基因編輯移植安全監測框架的監管
  • 利用區塊鏈提高透明度的去中心化器官共用網路的出現
  • 利用去細胞化和再細胞化方法開發生物工程器官

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章 器官移植市場（依器官類型）

  • 心
  • 腸子
  • 腎
  • 肝
  • 肺
  • 胰臟

第9章 移植市場（依產品類型）

  • 耗材
    • 導管
    • 接枝
    • 縫合線
  • 裝置
    • 監控設備
    • 灌注裝置
    • 保存液
  • 植入
    • 人造器官
    • 血管移植物
  • 製藥
    • 抗增生藥物
    • Calcineurin抑制劑
    • 皮質類固醇
    • mTOR抑制劑

第 10 章 器官移植市場（依捐贈者類型）

  • 已故捐贈者
  • 活體捐贈者

第11章 移植市場（依手術類型）

  • 腹腔鏡
  • 打開
  • 機器人

第12章 移植市場（依最終用戶分類）

  • 門診手術中心
  • 醫院
  • 專科診所

第13章 器官移植市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 器官移植市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國移植市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Novartis AG
    • F. Hoffmann-La Roche AG
    • Astellas Pharma Inc.
    • Pfizer Inc.
    • Johnson & Johnson
    • Bristol-Myers Squibb Company
    • Sanofi SA
    • Merck KGaA
    • Teva Pharmaceutical Industries Ltd.
    • Baxter International Inc.
Product Code: MRR-031685195793

The Transplantation Market is projected to grow by USD 60.98 billion at a CAGR of 8.78% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 31.09 billion
Estimated Year [2025] USD 33.80 billion
Forecast Year [2032] USD 60.98 billion
CAGR (%) 8.78%

A concise primer on how clinical innovations, preservation technologies, and procedural shifts are reshaping transplantation care delivery and commercial priorities

Transplantation medicine is at a pivotal juncture, driven by advances in surgical techniques, biotechnologies, and organ preservation methods that are redefining clinical possibilities. Recent innovations in perfusion and preservation, together with enhanced immunosuppressive regimens, have extended viable windows for transplantation and enabled more complex procedures. Concurrently, shifts in donor management and the rise of minimally invasive and robotic approaches are altering care pathways, requiring hospital systems and suppliers to rethink logistics, procurement, and training frameworks.

This report synthesizes clinical, technological, regulatory, and payer-facing dynamics to present an integrated executive perspective. It emphasizes how product portfolios-from consumables such as catheters, grafts, and sutures to devices including monitoring and perfusion systems, and implants like artificial organs and vascular grafts-interact with evolving procedural choices and donor profiles. The narrative connects operational realities in ambulatory surgical centers, hospitals, and specialty clinics with broader trends in clinical outcomes and patient access. Ultimately, this introduction frames transplantation as a sector with intersecting clinical complexity and commercial opportunity, setting the stage for the deeper analyses that follow.

How shifts in surgical approaches, organ preservation science, and outcome-focused reimbursement models are collectively transforming the transplantation ecosystem

The transplantation landscape is experiencing transformative shifts across clinical practice, technology adoption, and policy environments that together recalibrate competitive advantage. Clinically, there is a clear movement from traditional open procedures to robotic-assisted and laparoscopic techniques, driven by the desire to reduce perioperative morbidity and accelerate recovery. This trend is accompanied by a growing emphasis on precision management of immunosuppression, where newer agents and combination strategies aim to reduce rejection while mitigating long-term adverse effects.

Technological shifts are equally consequential. The maturation of organ perfusion and preservation solutions has improved organ viability, while advances in monitoring devices enable more granular perioperative and post-transplant management. At the same time, implants-ranging from advanced vascular grafts to nascent artificial organ prototypes-are progressing from concept to clinical feasibility, prompting re-examination of care pathways. Regulatory and reimbursement environments are adapting to these innovations, with payers and health systems increasingly rewarding demonstrable improvements in patient outcomes and total cost of care. Taken together, these forces are not incremental; they are reshaping procurement priorities, clinical team competencies, and long-term strategic roadmaps across providers and suppliers.

Assessment of the operational and strategic consequences of United States tariff adjustments in 2025 on transplantation supply chains and procurement resilience

Tariff policy changes in the United States in 2025 introduced discrete pressures across the transplantation supply chain, influencing sourcing strategies, supplier relationships, and cost structures. Increased duties on certain imported components and raw materials have raised landed costs for manufacturers of devices, consumables, and implants, prompting procurement teams to revisit supplier diversification and nearshoring options. These dynamics have had ripple effects on inventory practices and lead-time buffers, as healthcare providers balance cost containment with the imperative to maintain continuity of care for time-sensitive procedures.

In response, many manufacturers accelerated efforts to localize critical manufacturing steps or to qualify alternative sources that reduce exposure to tariff volatility. Clinical and supply chain leaders adapted by strengthening demand forecasting and by negotiating service-level agreements that emphasize resilience. Additionally, there has been renewed interest in value-based contracting and bundled payment structures that can absorb episodic cost pressures while aligning incentives across stakeholders. While regulatory compliance and quality assurance remain paramount, the tariffs catalyzed a broader reassessment of supply resilience and strategic procurement that will influence supplier selection and partnership models going forward.

Integrated segmentation intelligence that connects organ-specific clinical needs, product hierarchies, donor pathways, procedural choices, and care settings to inform strategic prioritization

A nuanced understanding of the transplantation landscape requires integrating insights across five segmentation lenses that together capture clinical, product, donor, procedural, and end-user variability. When analyzed by organ type, clinical priorities and device needs differ substantially between heart, intestine, kidney, liver, lung, and pancreas transplantation; for example, organ-specific preservation requirements and post-operative monitoring protocols shape product demand and clinical workflows. From a product type perspective, the ecosystem spans consumables such as catheters, grafts, and sutures; devices including monitoring devices, perfusion devices, and preservation solutions; implants covering artificial organs and vascular grafts; and pharmaceuticals comprising antiproliferative agents, calcineurin inhibitors, corticosteroids, and mTOR inhibitors. This product hierarchy underscores where incremental innovation and supply constraints exert the greatest operational impact.

Donor type segmentation divides practice between deceased donor and living donor pathways, each presenting distinct logistical and ethical considerations that affect procurement timelines, consent processes, and preoperative optimization. Procedure type segmentation highlights the differing resource profiles and training demands associated with laparoscopic, open, and robotic procedures, which in turn alter capital planning and perioperative staffing models. Finally, end-user segmentation across ambulatory surgical centers, hospitals, and specialty clinics demonstrates how care setting influences adoption speed for new technologies, procurement cycles, and integration with existing clinical networks. Synthesizing these lenses allows stakeholders to tailor strategies that reflect clinical nuance and operational realities rather than one-size-fits-all assumptions.

Regional strategic perspectives reflecting how clinical capacity, regulatory frameworks, and procurement norms vary across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape adoption trajectories, regulatory touchpoints, and partnership opportunities across the transplantation landscape. In the Americas, clinical centers of excellence often drive early implementation of advanced preservation systems and robotic techniques, while procurement models vary between public and private payers, influencing purchasing cycles and contracting structures. Europe, the Middle East & Africa present a heterogeneous mosaic in which regulatory alignment, infrastructure disparities, and cross-border collaboration on organ sharing protocols create both opportunities and operational complexity; this region frequently emphasizes multicenter registries and guideline harmonization to elevate outcomes.

Asia-Pacific is characterized by rapid investment in surgical capacity, growing clinical research activity, and increasing local manufacturing capabilities that can reshape global supply relationships. Across all regions, reimbursement frameworks, workforce training pipelines, and national policies on donor registries influence how quickly new technologies move from approval to routine use. Consequently, commercial strategies that succeed in one geography often require recalibration to accommodate differences in procurement norms, regulatory expectations, and clinical practice patterns in another, making regionally informed roadmaps essential for international players.

Competitive and partnership dynamics across device makers, biopharmaceutical firms, and specialist innovators that are shaping the future of transplantation product and service offerings

Competitive dynamics in transplantation are defined less by a single dominant player and more by ecosystem orchestration involving device manufacturers, pharmaceutical firms, hospitals, and niche innovators. Established medical device companies continue to leverage scale, regulatory experience, and distribution networks to commercialize monitoring systems, perfusion platforms, and implantable technologies. Biopharmaceutical organizations focus on next-generation immunosuppressive regimens and adjunct therapies that improve graft longevity and patient quality of life. Meanwhile, smaller, specialized firms and academic spinouts contribute disruptive innovations in preservation chemistry, bioengineered graft materials, and artificial organ development.

Partnership strategies are increasingly central to competitive advantage; collaborations between clinical centers and industry accelerate real-world evidence generation and support payer engagement. Mergers and acquisitions are often driven by the desire to integrate complementary capabilities, such as combining device platforms with software-enabled monitoring or adding proprietary preservation solutions to a broader surgical portfolio. To differentiate, companies are investing in services that reduce clinical friction, including training programs, comprehensive maintenance, and digital tools for perioperative coordination. Overall, success favors organizations that align clinical value propositions with operational support and durable reimbursement strategies.

Action-centered strategic measures for executives to fortify supply resilience, accelerate clinical adoption, and align reimbursement with value delivery in transplantation

Leaders in the transplantation sector should pursue focused strategies that strengthen resilience, accelerate clinical adoption, and align stakeholder incentives. First, prioritize supply chain diversification and qualification of local manufacturing capacity for mission-critical components to mitigate exposure to tariff volatility and single-source dependencies. Second, invest in clinician training programs and clinical evidence generation that demonstrate improved patient outcomes and reduced total episode costs, facilitating more constructive payer conversations. Third, design bundled service offerings that combine devices, preservation solutions, clinical training, and post-operative monitoring to simplify procurement and deliver measurable value to hospitals and specialty clinics.

In parallel, executives should pursue strategic collaborations with high-performing transplant centers to co-develop and validate new technologies, supporting faster uptake and more persuasive value narratives. Embrace digital tools that enhance perioperative coordination and remote monitoring, as these can reduce complications and enable efficient use of limited specialist resources. Finally, maintain active engagement with regulators and reimbursement bodies to shape policy frameworks that recognize the clinical and economic benefits of advanced preservation technologies and integrated care models. By executing these recommendations, organizations can convert clinical innovation into sustainable commercial advantage.

Transparent research approach blending literature review, expert interviews, and data triangulation to produce validated, actionable insights across clinical and commercial domains

This research integrates qualitative and quantitative inputs to construct a holistic view of the transplantation ecosystem, combining systematic literature review, targeted expert interviews, and cross-functional data triangulation. The methodology began with an exhaustive review of peer-reviewed clinical studies, regulatory submissions, and guideline updates to establish the clinical and scientific foundation. This was complemented by structured interviews with transplant surgeons, procurement leaders, hospital administrators, and industry executives to capture operational nuances, unmet needs, and adoption barriers.

Secondary sources such as device registries, clinical trial repositories, and public policy documents were analyzed to validate trends and to map technology readiness levels. Triangulation techniques were applied to reconcile discrepancies across sources, and sensitivity checks ensured that operational interpretations were robust across geographies and care settings. Finally, segmentation frameworks were applied to align insights to organ type, product type, donor pathway, procedure type, and end-user context, enabling the development of actionable recommendations suited to different stakeholder priorities. Throughout, adherence to ethical research practices and data integrity standards guided evidence selection and synthesis.

Synthesis of actionable conclusions highlighting the converging drivers that will determine clinical adoption, operational resilience, and commercial success in transplantation

In conclusion, transplantation is poised at an inflection point where technological advances, shifting procedural norms, and evolving policy frameworks converge to create new clinical and commercial pathways. The interplay between organ-specific clinical challenges, a diverse product landscape encompassing consumables, devices, implants, and pharmaceuticals, and variable donor and procedural contexts underscores the need for differentiated strategies. Organizations that invest in resilient supply chains, evidence generation, clinician engagement, and integrated service models will be better positioned to translate innovation into sustained clinical impact.

Moving forward, success will depend on the ability to navigate regional regulatory heterogeneity, respond to procurement and reimbursement dynamics, and build partnerships that accelerate real-world adoption. By focusing on patient-centric outcomes, operational efficiency, and collaborative value delivery, stakeholders can contribute to a transplantation ecosystem that improves access, outcomes, and long-term graft survival while creating sustainable pathways for commercial growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing utilization of machine perfusion technologies to expand donor organ viability
  • 5.2. Rising adoption of xenotransplantation research to address critical organ shortages
  • 5.3. Integration of artificial intelligence algorithms in pre-operative donor organ matching workflows
  • 5.4. Growing regulatory focus on cell and gene edited graft safety monitoring frameworks
  • 5.5. Emergence of decentralized organ sharing networks leveraging blockchain for transparency
  • 5.6. Development of bioengineered organs using decellularization and recellularization methods

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transplantation Market, by Organ Type

  • 8.1. Heart
  • 8.2. Intestine
  • 8.3. Kidney
  • 8.4. Liver
  • 8.5. Lung
  • 8.6. Pancreas

9. Transplantation Market, by Product Type

  • 9.1. Consumables
    • 9.1.1. Catheters
    • 9.1.2. Grafts
    • 9.1.3. Sutures
  • 9.2. Devices
    • 9.2.1. Monitoring Devices
    • 9.2.2. Perfusion Devices
    • 9.2.3. Preservation Solutions
  • 9.3. Implants
    • 9.3.1. Artificial Organs
    • 9.3.2. Vascular Grafts
  • 9.4. Pharmaceuticals
    • 9.4.1. Antiproliferative Agents
    • 9.4.2. Calcineurin Inhibitors
    • 9.4.3. Corticosteroids
    • 9.4.4. Mtor Inhibitors

10. Transplantation Market, by Donor Type

  • 10.1. Deceased Donor
  • 10.2. Living Donor

11. Transplantation Market, by Procedure Type

  • 11.1. Laparoscopic
  • 11.2. Open
  • 11.3. Robotic

12. Transplantation Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Transplantation Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Transplantation Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Transplantation Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis AG
    • 16.3.2. F. Hoffmann-La Roche AG
    • 16.3.3. Astellas Pharma Inc.
    • 16.3.4. Pfizer Inc.
    • 16.3.5. Johnson & Johnson
    • 16.3.6. Bristol-Myers Squibb Company
    • 16.3.7. Sanofi S.A.
    • 16.3.8. Merck KGaA
    • 16.3.9. Teva Pharmaceutical Industries Ltd.
    • 16.3.10. Baxter International Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSPLANTATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSPLANTATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL TRANSPLANTATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TRANSPLANTATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS TRANSPLANTATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL TRANSPLANTATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. TRANSPLANTATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. TRANSPLANTATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TRANSPLANTATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TRANSPLANTATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TRANSPLANTATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSPLANTATION MARKET SIZE, BY HEART, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TRANSPLANTATION MARKET SIZE, BY HEART, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSPLANTATION MARKET SIZE, BY HEART, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TRANSPLANTATION MARKET SIZE, BY HEART, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSPLANTATION MARKET SIZE, BY HEART, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TRANSPLANTATION MARKET SIZE, BY HEART, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSPLANTATION MARKET SIZE, BY INTESTINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TRANSPLANTATION MARKET SIZE, BY INTESTINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSPLANTATION MARKET SIZE, BY INTESTINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TRANSPLANTATION MARKET SIZE, BY INTESTINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSPLANTATION MARKET SIZE, BY INTESTINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TRANSPLANTATION MARKET SIZE, BY INTESTINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSPLANTATION MARKET SIZE, BY KIDNEY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TRANSPLANTATION MARKET SIZE, BY KIDNEY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSPLANTATION MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TRANSPLANTATION MARKET SIZE, BY KIDNEY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSPLANTATION MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TRANSPLANTATION MARKET SIZE, BY KIDNEY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSPLANTATION MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TRANSPLANTATION MARKET SIZE, BY LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSPLANTATION MARKET SIZE, BY LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TRANSPLANTATION MARKET SIZE, BY LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSPLANTATION MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TRANSPLANTATION MARKET SIZE, BY LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSPLANTATION MARKET SIZE, BY PANCREAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TRANSPLANTATION MARKET SIZE, BY PANCREAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSPLANTATION MARKET SIZE, BY PANCREAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TRANSPLANTATION MARKET SIZE, BY PANCREAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSPLANTATION MARKET SIZE, BY PANCREAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TRANSPLANTATION MARKET SIZE, BY PANCREAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSPLANTATION MARKET SIZE, BY CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TRANSPLANTATION MARKET SIZE, BY CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSPLANTATION MARKET SIZE, BY CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TRANSPLANTATION MARKET SIZE, BY CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSPLANTATION MARKET SIZE, BY CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TRANSPLANTATION MARKET SIZE, BY CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSPLANTATION MARKET SIZE, BY GRAFTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TRANSPLANTATION MARKET SIZE, BY GRAFTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRANSPLANTATION MARKET SIZE, BY GRAFTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TRANSPLANTATION MARKET SIZE, BY GRAFTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSPLANTATION MARKET SIZE, BY GRAFTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TRANSPLANTATION MARKET SIZE, BY GRAFTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSPLANTATION MARKET SIZE, BY SUTURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TRANSPLANTATION MARKET SIZE, BY SUTURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRANSPLANTATION MARKET SIZE, BY SUTURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TRANSPLANTATION MARKET SIZE, BY SUTURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSPLANTATION MARKET SIZE, BY SUTURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TRANSPLANTATION MARKET SIZE, BY SUTURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TRANSPLANTATION MARKET SIZE, BY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TRANSPLANTATION MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TRANSPLANTATION MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TRANSPLANTATION MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TRANSPLANTATION MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRANSPLANTATION MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TRANSPLANTATION MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TRANSPLANTATION MARKET SIZE, BY PERFUSION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TRANSPLANTATION MARKET SIZE, BY PERFUSION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TRANSPLANTATION MARKET SIZE, BY PERFUSION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TRANSPLANTATION MARKET SIZE, BY PERFUSION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TRANSPLANTATION MARKET SIZE, BY PERFUSION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TRANSPLANTATION MARKET SIZE, BY PERFUSION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRESERVATION SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRESERVATION SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRESERVATION SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRESERVATION SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRESERVATION SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TRANSPLANTATION MARKET SIZE, BY PRESERVATION SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TRANSPLANTATION MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TRANSPLANTATION MARKET SIZE, BY ARTIFICIAL ORGANS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TRANSPLANTATION MARKET SIZE, BY ARTIFICIAL ORGANS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TRANSPLANTATION MARKET SIZE, BY ARTIFICIAL ORGANS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TRANSPLANTATION MARKET SIZE, BY ARTIFICIAL ORGANS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TRANSPLANTATION MARKET SIZE, BY ARTIFICIAL ORGANS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TRANSPLANTATION MARKET SIZE, BY ARTIFICIAL ORGANS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TRANSPLANTATION MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TRANSPLANTATION MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TRANSPLANTATION MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TRANSPLANTATION MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TRANSPLANTATION MARKET SIZE, BY VASCULAR GRAFTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TRANSPLANTATION MARKET SIZE, BY VASCULAR GRAFTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TRANSPLANTATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TRANSPLANTATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TRANSPLANTATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TRANSPLANTATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TRANSPLANTATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TRANSPLANTATION MARKET SIZE, BY ANTIPROLIFERATIVE AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TRANSPLANTATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TRANSPLANTATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TRANSPLANTATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TRANSPLANTATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TRANSPLANTATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TRANSPLANTATION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TRANSPLANTATION MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TRANSPLANTATION MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TRANSPLANTATION MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TRANSPLANTATION MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TRANSPLANTATION MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TRANSPLANTATION MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TRANSPLANTATION MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TRANSPLANTATION MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TRANSPLANTATION MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TRANSPLANTATION MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL TRANSPLANTATION MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL TRANSPLANTATION MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL TRANSPLANTATION MARKET SIZE, BY DECEASED DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL TRANSPLANTATION MARKET SIZE, BY DECEASED DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL TRANSPLANTATION MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL TRANSPLANTATION MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL TRANSPLANTATION MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL TRANSPLANTATION MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVING DONOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVING DONOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVING DONOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVING DONOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL TRANSPLANTATION MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL TRANSPLANTATION MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL TRANSPLANTATION MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL TRANSPLANTATION MARKET SIZE, BY LAPAROSCOPIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL TRANSPLANTATION MARKET SIZE, BY LAPAROSCOPIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL TRANSPLANTATION MARKET SIZE, BY LAPAROSCOPIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL TRANSPLANTATION MARKET SIZE, BY LAPAROSCOPIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL TRANSPLANTATION MARKET SIZE, BY OPEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL TRANSPLANTATION MARKET SIZE, BY OPEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL TRANSPLANTATION MARKET SIZE, BY OPEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL TRANSPLANTATION MARKET SIZE, BY OPEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL TRANSPLANTATION MARKET SIZE, BY OPEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL TRANSPLANTATION MARKET SIZE, BY OPEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL TRANSPLANTATION MARKET SIZE, BY ROBOTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL TRANSPLANTATION MARKET SIZE, BY ROBOTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL TRANSPLANTATION MARKET SIZE, BY ROBOTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL TRANSPLANTATION MARKET SIZE, BY ROBOTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL TRANSPLANTATION MARKET SIZE, BY ROBOTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL TRANSPLANTATION MARKET SIZE, BY ROBOTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL TRANSPLANTATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL TRANSPLANTATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL TRANSPLANTATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL TRANSPLANTATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL TRANSPLANTATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL TRANSPLANTATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL TRANSPLANTATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL TRANSPLANTATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL TRANSPLANTATION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL TRANSPLANTATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL TRANSPLANTATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL TRANSPLANTATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL TRANSPLANTATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL TRANSPLANTATION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL TRANSPLANTATION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL TRANSPLANTATION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL TRANSPLANTATION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL TRANSPLANTATION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL TRANSPLANTATION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL TRANSPLANTATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL TRANSPLANTATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS TRANSPLANTATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS TRANSPLANTATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS TRANSPLANTATION MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS TRANSPLANTATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA TRANSPLANTATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA TRANSPLANTATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA TRANSPLANTATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE TRANSPLANTATION MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE TRANSPLANTATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST TRANSPLANTATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. AFRICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. AFRICA TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. AFRICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. AFRICA TRANSPLANTATION MARKET SIZE, BY ORGAN TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. AFRICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. AFRICA TRANSPLANTATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. AFRICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 332. AFRICA TRANSPLANTATION MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 333. AFRICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 334. AFRICA TRANSPLANTATION MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 335. AFRICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 336. AFRICA TRANSPLANTATION MARKET SIZE, BY IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 337. AFRICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 338. AFRICA TRANSPLANTATION MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 339. AFRICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 340. AFRICA TRANSPLANTATION MARKET SIZE, BY DONOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 341. AFRICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 342. AFRICA TRANSPLANTATION MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 343. AFRICA TRANSPLANTATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 344. AFRICA TRANSPLANTATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 345. ASIA-PACIFIC TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)

TABLE 3